1. Home
  2. KALV
  3. KALV News

Latest KalVista Pharmaceuticals Inc. (KALV) News on September 7, 2025

KALV

CNW Group

2 months ago

Pendopharm® and KalVista® Partner to Bring First Oral On-Demand HAE Treatment to Canada

KALV

MT Newswires

2 months ago

Sector Update: Health Care Stocks Steady Pre-Bell Thursday

KALV

MT Newswires

2 months ago

KalVista Grants Pendopharm Rights to Commercialize its Angioedema Treatment in Canada

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
KALV

Business Wire

2 months ago

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

How KalVista Pharma Is Taking On A Rare But Deadly Disease
KALV

Investor's Business Daily

3 months ago

How KalVista Pharma Is Taking On A Rare But Deadly Disease

KALV

MT Newswires

3 months ago

DRI Healthcare Notes FDA Delay for KalVista's' Sebetralstat New Drug Approval on "Resourcing" Issues

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
KALV

Business Wire

3 months ago

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’
KALV

BioPharma Dive

3 months ago

FDA to miss approval deadline for Kalvista drug due to ‘resource constraints’

KALV

MT Newswires

3 months ago

KalVista Says FDA to Miss PDUFA Goal Date for Sebetralstat Application

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
KALV

Business Wire

3 months ago

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
KALV

Business Wire

3 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

3 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
KALV

Business Wire

3 months ago

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
KALV

Business Wire

3 months ago

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings
KALV

Business Wire

4 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

4 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference
KALV

Business Wire

4 months ago

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

KalVista licenses commercialisation rights for HAE to Kaken in Japan
KALV

Pharmaceutical Technology

5 months ago

KalVista licenses commercialisation rights for HAE to Kaken in Japan

KALV

MT Newswires

5 months ago

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
KALV

Business Wire

5 months ago

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

5 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference
KALV

Business Wire

5 months ago

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial
KALV

Clinical Trials Arena

5 months ago

KalVista Pharmaceuticals enrols all subjects in hereditary angioedema drug trial

KALV

MT Newswires

5 months ago

KalVista Pharmaceuticals Completes Participant Enrollment Ahead of Schedule for Pediatric Hereditary Angioedema Trial

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
KALV

Business Wire

5 months ago

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
KALV

Business Wire

6 months ago

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema
KALV

Business Wire

6 months ago

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

6 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
KALV

Business Wire

6 months ago

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
KALV

Business Wire

6 months ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
KALV

Business Wire

7 months ago

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting
KALV

Business Wire

7 months ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

7 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALV

MT Newswires

8 months ago

KalVista Says Japan Health Ministry Grants Orphan Drug Designation to Sebetralstat

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema
KALV

Business Wire

8 months ago

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

8 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALV

MT Newswires

9 months ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

KALV

MT Newswires

9 months ago

KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says

KalVista Appoints Jeb Ledell as Chief Operating Officer
KALV

Business Wire

9 months ago

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update
KALV

Business Wire

9 months ago

KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

9 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors
KALV

Business Wire

9 months ago

KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
KALV

Business Wire

10 months ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Secures $184M Financing for Sebetralstat Launch
KALV

TipRanks

10 months ago

KalVista Secures $184M Financing for Sebetralstat Launch

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

10 months ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALV

MT Newswires

10 months ago

KalVista Closes Royalty Financing Deal with DRI Healthcare, Prices $55 Million Offering

KALV

MT Newswires

10 months ago

DRI Healthcare Trust Acquires Royalty Stake in Global Sales of Sebetralstat

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million
KALV

Business Wire

10 months ago

KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust
KALV

Business Wire

10 months ago

KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology
KALV

Business Wire

10 months ago

KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema Forum

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In The United States
KALV

Simply Wall St.

a year ago

High Growth Tech Stocks To Watch In The United States

KALV

MT Newswires

a year ago

KalVista Submits Marketing Applications for Angioedema Treatment Sebetralstat

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema
KALV

Business Wire

a year ago

KalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)

KALV

MT Newswires

a year ago

KalVista Pharmaceuticals Names Brian Piekos Finance Chief

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference
KALV

Business Wire

a year ago

KalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare Conference

KalVista Appoints Brian Piekos as Chief Financial Officer
KALV

Business Wire

a year ago

KalVista Appoints Brian Piekos as Chief Financial Officer

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALV

MT Newswires

a year ago

KalVista Says New Drug Application for Sebetralstat Accepted by FDA

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema
KALV

Business Wire

a year ago

KalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary Angioedema

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin Symposium

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema
KALV

Business Wire

a year ago

KalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary Angioedema

Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
KALV

Simply Wall St.

a year ago

Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KALV

MT Newswires

a year ago

KalVista Starts Hereditary Angioedema Trial in Pediatric Patients

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11
KALV

Business Wire

a year ago

KalVista Initiates KONFIDENT-KID Trial for On-demand Treatment of Hereditary Angioedema Attacks with Sebetralstat in Children Aged 2 to 11

KALV

MT Newswires

a year ago

KalVista Pharmaceuticals Submits New Drug Application to FDA for Investigational Hereditary Angioedema Treatment

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema
KALV

Business Wire

a year ago

KalVista Submits New Drug Application to FDA for Sebetralstat as First Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema

KALV

MT Newswires

a year ago

KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024

Breakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)
KALV

Simply Wall St.

a year ago

Breakeven On The Horizon For KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
KALV

Business Wire

a year ago

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors
KALV

Barrons.com

a year ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
KALV

Business Wire

a year ago

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas
KALV

Business Wire

a year ago

KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer
KALV

Business Wire

a year ago

KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference
KALV

Business Wire

2 years ago

KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
KALV

Business Wire

2 years ago

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
KALV

Business Wire

2 years ago

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
KALV

Business Wire

2 years ago

KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
KALV

Business Wire

2 years ago

KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
KALV

Business Wire

2 years ago

KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Share on Social Networks: